Genocea Biosciences, Inc. (GNCA) Hits New 52-Week Low at $1.54
Shares of Genocea Biosciences, Inc. (NASDAQ:GNCA) reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $1.54 and last traded at $1.51, with a volume of 5,432,543 shares trading hands. The stock had previously closed at $5.33.
A number of analysts have issued reports on the stock. Zacks Investment Research cut shares of Genocea Biosciences from a “buy” rating to a “hold” rating in a research note on Monday, June 5th. ValuEngine upgraded shares of Genocea Biosciences from a “sell” rating to a “hold” rating in a research note on Monday, July 24th. Stifel Nicolaus cut shares of Genocea Biosciences from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $15.00 to $2.50 in a research note on Monday. Piper Jaffray Companies restated an “overweight” rating and issued a $18.00 price objective (up from $17.00) on shares of Genocea Biosciences in a research note on Tuesday, July 25th. Finally, Needham & Company LLC cut shares of Genocea Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $10.23.
The firm’s market cap is $34.06 million. The stock’s 50 day moving average is $4.75 and its 200 day moving average is $5.55.
Genocea Biosciences (NASDAQ:GNCA) last posted its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.54) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.08). On average, equities research analysts forecast that Genocea Biosciences, Inc. will post ($1.92) earnings per share for the current fiscal year.
In other news, CFO Jonathan Poole sold 45,000 shares of Genocea Biosciences stock in a transaction on Monday, July 24th. The stock was sold at an average price of $6.00, for a total transaction of $270,000.00. Following the completion of the sale, the chief financial officer now owns 84,247 shares of the company’s stock, valued at $505,482. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 6.70% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently modified their holdings of GNCA. GSA Capital Partners LLP bought a new position in shares of Genocea Biosciences in the second quarter worth $100,000. Ameriprise Financial Inc. grew its position in Genocea Biosciences by 11.5% in the second quarter. Ameriprise Financial Inc. now owns 22,233 shares of the biotechnology company’s stock valued at $119,000 after acquiring an additional 2,300 shares during the last quarter. State of Wisconsin Investment Board bought a new position in Genocea Biosciences in the second quarter valued at about $125,000. Keybank National Association OH bought a new position in Genocea Biosciences in the first quarter valued at about $147,000. Finally, Rhumbline Advisers bought a new position in Genocea Biosciences in the second quarter valued at about $157,000. Institutional investors own 59.25% of the company’s stock.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
Receive News & Stock Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related stocks with our FREE daily email newsletter.